The majority of patients with wet age-related macular degeneration who received aflibercept 8 mg maintained extended dosing intervals through 2 years in a pivotal trial, according to a press release from Regeneron.
The double-masked, active-controlled PULSAR trial is investigating the noninferiority of aflibercept 8 mg at dosing regimens of 12 weeks (335 patients) and 16 weeks (338 patients) compared with Eylea (aflibercept 2 mg) at a dosing regimen of 8 weeks (336 patients), with all participants receiving three initial monthly doses.
At the end of 2 years, 88% of patients (Read more...)